Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jun 18:25:15040.
doi: 10.1038/npjpcrm.2015.40.

Assessment of the safety of long-acting β2-agonists in routine asthma care: the ASTRO-LAB protocol

Affiliations
Review

Assessment of the safety of long-acting β2-agonists in routine asthma care: the ASTRO-LAB protocol

Eric Van Ganse et al. NPJ Prim Care Respir Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study flowchart for patient enrolment and follow-up.
Figure 2
Figure 2
Summary of patient- and physician-reported data at inclusion and during follow-up.

References

    1. Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med. 2010;362:1169–1171. - PubMed
    1. Cates CJ, Jaeschke R, Schmidt S, Ferrer M. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev. 2013;3:CD006922. - PubMed
    1. Cates CJ, Jaeschke R, Schmidt S, Ferrer M. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev. 2013;6:CD006924. - PubMed
    1. Strom BL. Pharmacoepidemiology. John Wiley & Sons Ltd; 2008. pp. 1–889.
    1. Hernández G, Avila M, Pont À, Garin O, Alonso J, Laforest L. Long-acting beta-agonists plus inhaled corticosteroids safety: a systematic review and meta-analysis of non-randomized studies. Respir Res. 2014;15:83. - PMC - PubMed

Publication types

MeSH terms

Substances